fludarabine has been researched along with Hepatitis C in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, HS; Niihara, Y; Yospur, L | 1 |
| Baccarani, M; Fanin, R; Patriarca, F; Silvestri, F; Sperotto, A; Zaja, F | 1 |
2 other study(ies) available for fludarabine and Hepatitis C
| Article | Year |
|---|---|
Chronic lymphocytic leukemia in a patient with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Chronic Disease; Fatal Outcome; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1998 |
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment.
Topics: Adult; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Male; Recombinant Proteins; Remission Induction; Time Factors; Vidarabine | 2001 |